Background: Selecting patients who potentially benefit from immune checkpoint inhibitors
(ICIs) is critical. Programmed death ligand-1 (PD-L1) protein immunohistochemical …

Objective The aim of this study was to identify baseline peripheral blood biomarkers
associated with clinical outcome in patients with NSCLC treated with nivolumab. Methods …

Background Anti-programmed cell death 1 (PD-1) antibodies have demonstrated improved
overall survival (OS) and progression-free survival (PFS) in a subset of patients with …

Objectives We aimed to examine clinical data and baseline blood test results as potential
predictive biomarkers for benefit from nivolumab, in advanced non-small cell lung cancer …

Immune checkpoint inhibitors, as nivolumab, are used in advanced non-small cell lung
cancer (NSCLC). However, no associated biomarker is validated in clinical practice with this …

Objectives Nivolumab, an anti-programmed cell death protein 1 (PD-1) monoclonal
antibody, has been shown to yield a durable response and significant prolongation of the …

Background Explore markers to predict the clinical outcomes of checkpoint inhibitors have
high unmet needs. The following study investigates whether hematologic parameter such as …

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape of non-
small cell lung cancer (NSCLC), either used in monotherapy or in combination with …

Lung cancer is the most common malignancy worldwide. Despite significant advances in
diagnosis and treatment, mortality rates remain extremely high, close to incidence rates …

Background Nivolumab offers a superior survival benefit over docetaxel in patients with
advanced, previously treated non-small-cell lung cancer (NSCLC). An association between …